Follow
Ravi Salgia
Ravi Salgia
Verified email at coh.org
Title
Cited by
Cited by
Year
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
51042010
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
31442014
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
18852014
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
14372012
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
10872011
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
J Gong, A Chehrazi-Raffle, S Reddi, R Salgia
Journal for immunotherapy of cancer 6, 1-18, 2018
9572018
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen, J Burrows, R Salgia
Cancer letters 225 (1), 1-26, 2005
8982005
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups
MT Jaklitsch, FL Jacobson, JHM Austin, JK Field, JR Jett, S Keshavjee, ...
The Journal of thoracic and cardiovascular surgery 144 (1), 33-38, 2012
6592012
c-Met: structure, functions and potential for therapeutic inhibition
PC Ma, G Maulik, J Christensen, R Salgia
Cancer and Metastasis Reviews 22, 309-325, 2003
6582003
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non–small cell lung cancer
PC Ma, R Jagadeeswaran, S Jagadeesh, MS Tretiakova, V Nallasura, ...
Cancer research 65 (4), 1479-1488, 2005
6392005
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsMET Exon 14 Alterations Confer …
GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ...
Cancer discovery 5 (8), 850-859, 2015
6362015
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
G Maulik, A Shrikhande, T Kijima, PC Ma, PT Morrison, R Salgia
Cytokine & growth factor reviews 13 (1), 41-59, 2002
6062002
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ...
Journal of Clinical Oncology 29 (19), 2660, 2011
5882011
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
PC Ma, T Kijima, G Maulik, EA Fox, M Sattler, JD Griffin, BE Johnson, ...
Cancer research 63 (19), 6272-6281, 2003
5612003
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
J Rehman, HJ Zhang, PT Toth, Y Zhang, G Marsboom, Z Hong, R Salgia, ...
The FASEB Journal 26 (5), 2175, 2012
5042012
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with …
SHI Ou, EL Kwak, C Siwak-Tapp, J Dy, K Bergethon, JW Clark, ...
Journal of thoracic oncology 6 (5), 942-946, 2011
4692011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
JK Lennerz, EL Kwak, A Ackerman, M Michael, SB Fox, K Bergethon, ...
Journal of clinical oncology 29 (36), 4803, 2011
4632011
Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer
DVT Catenacci, MR Junttila, T Karrison, N Bahary, MN Horiba, SR Nattam, ...
Journal of Clinical Oncology 33 (36), 4284, 2015
4452015
Molecular abnormalities in lung cancer.
R Salgia, AT Skarin
Journal of Clinical Oncology 16 (3), 1207-1217, 1998
4401998
The role of ephrins and Eph receptors in cancer
H Surawska, PC Ma, R Salgia
Cytokine & growth factor reviews 15 (6), 419-433, 2004
4102004
The system can't perform the operation now. Try again later.
Articles 1–20